Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Buprenorphine
Napp Pharmaceuticals Ltd
N02AE01
Buprenorphine
20microgram/1hour
Transdermal patch
Transdermal
Schedule 3 (CD No Register)
Valid as a prescribable product
BNF: 04070200; GTIN: 5012854036178
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT _BUTRANS_ _®_ _ _5 MICROGRAM/HOUR TRANSDERMAL PATCHES _BUTRANS_ _®_ _ _10 MICROGRAM/HOUR TRANSDERMAL PATCHES _BUTRANS_ _®_ _ _20 MICROGRAM/HOUR TRANSDERMAL PATCHES Buprenorphine • THESE PATCHES CONTAIN A STRONG PAIN KILLER • ENSURE THAT OLD PATCHES ARE REMOVED BEFORE APPLYING A NEW ONE • PATCHES MUST NOT BE CUT • DO NOT EXPOSE THE PATCHES TO A HEAT SOURCE (SUCH AS A HOT WATER BOTTLE) • DO NOT SOAK IN A HOT BATH OR TAKE A HOT SHOWER WHILST WEARING A PATCH • IF YOU DEVELOP A FEVER TELL YOUR DOCTOR IMMEDIATELY • FOLLOW THE DOSAGE INSTRUCTIONS CAREFULLY AND ONLY CHANGE YOUR PATCH ON THE SAME DAY AND AT THE SAME TIME 7 DAYS LATER • IF YOUR BREATHING BECOMES SHALLOW AND WEAK TAKE THE PATCH OFF AND SEEK MEDICAL HELP READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor, pharmacist or nurse. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What _BUTRANS_ patches are and what they are used for 2. What you need to know before you use _BUTRANS_ patches 3. How to use _BUTRANS_ patches 4. Possible side effects 5. How to store _BUTRANS_ patches 6. Content of the pack and other information 1. WHAT _BUTRANS_ PATCHES ARE AND WHAT THEY ARE USED FOR _BUTRANS_ patches contain the active ingredient buprenorphine which belongs to a group of medicines called strong analgesics or ‘painkillers’. They have been prescribed for you by your doctor to relieve moderate, long-lasting pain that requires the use of a strong painkiller. _ _ _BUTRANS_ patches should not be used to relieve acute pain. _ _ _BUTRANS_ patches act t Read the complete document
OBJECT 1 BUTRANS 5UG/H TRANSDERMAL PATCH Summary of Product Characteristics Updated 18-Apr-2017 | Napp Pharmaceuticals Limited 1. Name of the medicinal product _BUTRANS _5 microgram/hour, transdermal patch BuTrans 10 microgram/hour transdermal patch BuTrans 20 microgram/hour transdermal patch 2. Qualitative and quantitative composition Each transdermal patch contains 5 mg of buprenorphine in a 6.25 cm 2 area releasing a nominal 5 micrograms of buprenorphine per hour over a period of 7 days. Each transdermal patch contains 10 mg of buprenorphine in a 12.5 cm2 area releasing a nominal 10 micrograms of buprenorphine per hour over a period of 7 days. Each transdermal patch contains 20 mg of buprenorphine in a 25 cm2 area releasing a nominal 20 micrograms of buprenorphine per hour over a period of 7 days. For the full list of excipients, see section 6.1. 3. Pharmaceutical form Transdermal patch. Beige coloured patch with rounded corners. Square patch marked: _BUTRANS_ 5 μg/h Beige coloured patch with rounded corners Rectangular patch marked BuTrans 10 ug/h Beige coloured patch with rounded corners Square patch marked: BuTrans 20 μg/h 4. Clinical particulars 4.1 Therapeutic indications Treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia _BUTRANS _is not suitable for the treatment of acute pain. _BUTRANS _is indicated in adults 4.2 Posology and method of administration Posology _BUTRANS _should be administered every 7th day. _Patients aged 18 years and over_: The lowest _BUTRANS_ dose (_BUTRANS_ 5 microgram/hour transdermal patch) should be used as the initial dose. Consideration should be given to the previous opioid history of the patient (see section 4.5) as well as to the current general condition and medical status of the patient. _Titration_: During initiation of treatment with _BUTRANS_, short-acting supplemental analgesics may be required (see section 4.5) as needed until analgesic efficacy with _BUTRANS _is attained. The dose of _BUTRANS_ may be t Read the complete document